CurrentHawaii Medical Service Association (HMSA)Policy N/A

Prior authorization criteria for osteoporosis and related indications (denosumab/other injectable osteoporosis agents)

A prior authorization request form and decision tree used by CVS Caremark (for HMSA patients) to determine coverage of specified osteoporosis medications (e.g., Prolia, Xgeva-like/denosumab brands and other listed products) across indications including postmenopausal osteoporosis, male osteoporosis, glucocorticoid-induced osteoporosis, breast cancer- or prostate cancer-related bone loss. It captures required clinical information (diagnosis, DEXA T-score, FRAX, prior therapy, fragility fractures) and documents when approval may be granted.

Policy Summary

PayerHawaii Medical Service Association (HMSA)

PolicyPrior authorization criteria for osteoporosis and related indications (denosumab/other injectable osteoporosis agents)

Policy CodePolicy N/A

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionProviders must complete and fax the prior authorization form with required supporting documentation (diagnosis, DEXA T-score, FRAX scores, documentation of prior bisphosphonate/injectable therapy failure or contraindication, glucocorticoid dose/duration, fracture documentation) to CVS Caremark at 1-866-237-5512.

SourceLink

POLICY UPDATE CHANGES

No material changes to clinical coverage criteria.

5Primary indication branches (postmenopausal, male, glucocorticoid-induced, breast, prostate)

3Key numeric thresholds (DEXA, FRAX, glucocorticoid dose)

2Required prior therapy conditions (bisphosphonate, injectable)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

This document is a prior authorization request form and decision tree used by CVS Caremark (for HMSA patients) to determine coverage for specified osteoporosis medications across multiple indications including postmenopausal osteoporosis, male osteoporosis, glucocorticoid-induced osteoporosis, and cancer-related bone loss. It operationalizes authorization by capturing required clinical information (diagnosis, DEXA T-score, FRAX scores, prior therapy history, fragility fracture documentation) and specifies when approval may be granted. The coverage stance is mixed and the policy status is CURRENT.

Key clinical thresholds

DEXA T-score (osteoporotic)<= -2.5

DEXA T-score (osteopenia range)< -1 to > -2.5

FRAX 10-year major osteoporotic fracture risk threshold> 20%

FRAX 10-year hip fracture risk threshold> 3%

Glucocorticoid exposure for GIOP pathway>= 2.5 mg/day prednisone equivalent for >= 3 months

Required bisphosphonate trial duration for failure/intolerance>= 1 year (oral or injectable)

Maximum duration - Evenity (romosozumab)12 months

Maximum duration - Forteo (teriparatide)24 months

Medical-Necessity Criteria and Decision Trees

Coding

Requested products listed on formmixed

	Prolia (listed as product option on form)
	Jubbonti (listed)
	Stoboclo (listed)
	Conexxence (listed)
	Ospomyv (listed)

ICD-10ICD-10

Form asks: 'What is the ICD-10 code?' - specific codes to be provided by prescriber

Provider Actions & Submission Requirements

Prior Authorization

Submit prior authorization request to CVS Caremark

Providers must complete and fax the prior authorization form with required supporting documentation (diagnosis, DEXA T-score, FRAX scores, documentation of prior bisphosphonate/injectable therapy failure or contraindication, glucocorticoid dose/duration, fracture documentation) to CVS Caremark at 1-866-237-5512.

Fax: 1-866-237-5512

Documentation Required

Submit objective test results

Attach pretreatment DEXA T-score and documented FRAX calculations and records supporting prior therapy failure/intolerance or clinical reasons to avoid bisphosphonates.

DEXA T-score (pretreatment)
FRAX calculations (major and hip)
Documentation of prior bisphosphonate/injectable therapy failure or intolerance

Background & Definitions

The form operationalizes prior authorization determinations for osteoporosis therapies administered or dispensed in various settings and asks the provider to fax completed requests and supporting documentation to CVS Caremark. It requests the diagnosis, DEXA T-score, FRAX scores, documentation of prior bisphosphonate or injectable therapy failure or intolerance, clinical reasons to avoid bisphosphonates, fragility fracture evidence, and—where relevant—glucocorticoid dose and duration. Approvals may be subject to dosing limits per FDA-approved labeling, accepted compendia, and evidence-based practice guidelines.

Definitions

Policy scope and thresholds summary

Revision History

No dated revision entries were provided in the brief; document-level changes will be populated by the system-level changes_list component.